Intranasal Corticosteroids Market Trends

Growth Drivers

Growing Geriatric Population with Low Autoimmune System to Hike the Market Growth:- Based on the statistics provided by the World Bank, in 2020, the global geriatric population was stated to be 723,595,779.

Increasing Sector of Cold & Cough Remedies - As of 2022, the cold & cough remedies sector was valued at approximately USD 40 billion.

Higher Prevalence of Cold and Flu - As per the report provided by the National Library of Medicine (NLM) in 2019, nearly 0.3 million people died on account of influenza across the globe.

Significant Demand in Allergic Rhinitis Treatment - The industry for global allergic rhinitis treatment is anticipated to reach around USD 7 billion by the year 2024.

Escalating per Capita Healthcare Expenditure Across the Globe - World Health Organization published a report demonstrating healthcare expenditure per capita in 2019 to be USD 1,121.97.

Challenges

Possibility of Side Effects such as Crusting and Nosebleed
Significant Number of People with Rhinophobia
Presence of Alternative Methods to Treat Allergies

Global Intranasal Corticosteroids Market: Key Insights

Base Year	2024
Forecast Year	2025-2037
CAGR	5.1%
Base Year Market Size (2024)	USD 7.13 billion
Forecast Year Market Size (2037)	USD 13.61 billion
Regional Scope	North America (U.S., and Canada) Asia Pacific (Japan, China, India, Indonesia, Malaysia, Australia, South Korea, Rest of Asia Pacific) Europe (UK, Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe) Latin America (Mexico, Argentina, Brazil, Rest of Latin America) Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of intranasal corticosteroids is estimated at USD 7.44 billion.

Intranasal Corticosteroids Market size was valued at USD 7.13 billion in 2024 and is likely to cross USD 13.61 billion by 2037, registering more than 5.1% CAGR during the forecast period i.e., between 2025-2037.

Asia Pacific industry is predicted to account for largest revenue share by 2037, on account of higher prevalence of type 1 diabetes, rheumatoid arthritis, and other types of sclerosis.

The major players in the market are AstraZeneca PLC, Sunovion Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., Johnson & Johnson Services, Inc., GSK plc, Sanofi S.A., Ivax Pharmaceuticals, Inc., OptiNose US, Inc., Chattem Chemicals, Inc., and Intersect ENT Inc.

Intranasal Corticosteroids Market Trends